UiPath (PATH) Valuation Check As Screen Agent Leads OSWorld Agentic AI Benchmark

Investor focus on UiPath (PATH) has picked up after the company said its Screen Agent, powered by Claude Opus 4.5, ranked first on the OSWorld Verified benchmark for agentic AI deployments.

See our latest analysis for UiPath.

Even with the Screen Agent milestone and growing attention on its AI roadmap, UiPath’s short-term share price performance has been weak, with a 7 day share price decline of 13.85% and a 1 day share price decline of 3.76%. Its 1 year total shareholder return of 14.96% and 3 year total shareholder return of 10.58% suggest longer term holders have still seen gains as sentiment has shifted around executive share sales, index inclusion in the S&P 1000, and the launch of a 2x leveraged PATH ETF.

If this kind of AI activity has your attention, it could be a good moment to scan high growth tech and AI stocks and see what other automation and software names fit your criteria.

With PATH trading around US$15.37 and a value score of 2, plus a modest discount to both analyst targets and some intrinsic estimates, you have to ask: is there real upside left here, or is the market already pricing in future growth?

Most Popular Narrative: 5.5% Undervalued

On this view, UiPath’s fair value of about US$16.27 sits modestly above the last close at US$15.37, which sets up a measured optimism around future profits and multiples.

UiPath's commitment to cloud offerings, with over $975 million in cloud ARR, positions the company to capitalize on AI-driven products and services, which could contribute to revenue growth and improved gross margins.

Read the complete narrative.

Curious how a relatively small gap between price and fair value leans on automation demand, margin upgrades and a future earnings multiple that assumes real staying power? The full narrative lays out how revenue mix, profitability shifts and valuation all connect for UiPath.

Result: Fair Value of $16.27 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there is still a real chance that deal delays tied to geopolitics and FX headwinds on revenue could blunt the optimistic narrative around automation and AI.

Find out about the key risks to this UiPath narrative.

Build Your Own UiPath Narrative

If you look at the numbers and reach a different conclusion, or simply prefer to build your own view from the ground up, you can pull the data together and shape a full UiPath thesis in just a few minutes, then Do it your way.

A great starting point for your UiPath research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If UiPath is on your radar, do not stop there. Broaden your watchlist with other ideas that might match your style and risk comfort.

• Target potential mispricings by scanning these 882 undervalued stocks based on cash flows that align with your approach to fundamentals and price.
• Spot emerging opportunities in automation and machine learning by reviewing these 25 AI penny stocks that could complement or contrast with your view on UiPath.
• Add sector variety by checking out these 30 healthcare AI stocks that combine data driven medicine with AI enabled tools.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com